



For Immediate Release

April 8, 2025

Acuitas Therapeutics Named One of Canada's Top Small & Medium Employers

Vancouver, B.C. – Today, Acuitas Therapeutics, Inc. was named one of [Canada's Top Small & Medium Employers \(2025\)](#). The Vancouver-based, privately held biotechnology firm is the global leader in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.

“It is an honour – once again – to be named one of Canada’s Top Small & Medium Employers,” said Chief Operating Officer Abi Coman-Walker. She added: “From day one, everyone at Acuitas has been driven by a strong commitment to fostering a culture where each team member feels respected, heard and valued. Our team includes some of the world’s leading scientists and business professionals – and our shared passion unites us in advancing scientific research that improves lives globally. Our dedication to innovation draws top-tier talent and cultivates a workplace of collaboration, creativity and a genuine sense of belonging. It’s a powerful combination that propels us forward as we work with partners to make the world healthier.”

About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is the global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas’ LNP technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works on identification of potent new lipids to enable partners to develop improved and new vaccines to prevent a range of infectious diseases (i.e., malaria, HIV/AIDS and tuberculosis), multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-